Navigation Links
Flip-flopping gene expression can be advantageous
Date:11/26/2007

One gene for pea pod color generates green pods while a variant of that gene gives rise to the yellow-pod phenotype, a feature that helped Gregor Mendel, the 19th century Austrian priest and scientist, first describe genetic inheritance. However, many modern-day geneticists are focused on the strange ability of some genes to be expressed spontaneously in either of two possible ways.

In order to better understand this phenomenon of epigenetic multistability, a major complication for Mendelian genetics, scientists at UC San Diego grew virtual bacterial cells in a computer experiment. They created a two-phenotype model system programmed to grow in ways that matched natural growth. In a deceptively simple experiment, they then recorded the degree to which the two phenotypes varied over time in individual cells, and then repeated the experiment over and over. They reported in the Nov. 19 online edition of Proceedings of the National Academy of Sciences (PNAS) that variability due to epigenetic multistability is larger and persists much longer than they had expected.

While the phenomenon is yet to be discovered in the human genome, the new results suggest that researchers studying bacteria should carefully design their experiments to measure variability due to epigenetic multistability. Even in human cells, multistability may play a role in genes can alternate between on and off settings.

Scientists studying bacteria have simply not had the tools to understand phenotypic variability, said Ting Lu, lead author of the study who was a UCSD graduate student in the lab of bioengineering professor Jeff Hasty. (Lu is currently a postdoctoral fellow at Princeton University.) Weve arrived at a theoretical framework that allows experimenters to measure the ephemeral nature of epigenetics.

Epigenetic multistability may be vital to cells that are outwardly different, but genetically identical. Only one of the two phenotypes m
'/>"/>

Contact: Rex Graham
ragraham@ucsd.edu
858-822-3075
University of California - San Diego  
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
2. 10th Anniversary of Revolutionary Teaching Approach that Offers the Severely Disabled the Gift of Self-Expression - Through Painting
3. New study shows that therapeutic gene expression can be sustainable for 1 year
4. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Flip-flopping gene expression can be advantageous
Flip-flopping gene expression can be advantageous
(Date:7/25/2008)...tiretroviral therapy may be due to genetic factors... A new study challenges the long-held belief that ...tem,s ability to restore itself after HIV patients...rapy (HAART). , From 50 percent to 90 percent o...CV. Intravenous drug use is the main cause of both...
(Date:7/25/2008)...ng overweight or obese is not only a personal issu...ealth issue that impacts other people in society. ...ch reveals that the extra Medicare cost associate...nificant financial burden on tax payers, costing u...tire current Medicare population. , The article...
(Date:7/25/2008)... consumers tips and encourages them to, ,Speak Up...., July 25 /PRNewswire-USNewswire/ -- The Pennsylv...onal Patient Safety Day" which,is a national effor...icipate fully in their healthcare by asking questi...urgery or illness., "We understand the important ...
(Date:7/25/2008)...the number of jobs created in the medical field sl...different kind of slowdown: they laid off fewer pe... Seattle, WA (PRWEB) July 25, 2008 -... field slowed in June overall, pharmaceutical comp...ill be music to the ears of sales representatives:...
Breaking Medicine News(10 mins):Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3
...ted by the type 3 virus which spreads by bugs and ...t most of the winegrowers have bought the national...free from the virus. New Zealand Winegrowers scien...said that a lot of research is being done to under...
... Journal of the National Cancer Institute, childho...premature menopause//. Ovarian irradiation and ce...ost common risk factors associated with early meno...hildren or adolescents diagnosed with cancer will ...
...MA) has issued a warning that the nation could be ... future due to a lack of clinical expertise. Dr M...the federal MPs and senators insisting for a strat... deal with the increase in number of students. He ...
...that inhabitants of Phet where hundreds of poultry...since they had a feast on these birds. Public hea...ichit are trying to create awareness of bird flu a...usly here. Dr. Prachak Wattanakun, a provincial he...
Other Medicine News:
(Date:7/24/2008)...W, Calif., July 24 /- Alexz... today that it has initiated,its second Phase 3 cl...Z-004 is an inhalation product candidate being dev...ients with schizophrenia or bipolar disorder.,Alex...id pharmacokinetic,(PK) properties resulting from ...
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Headlines claim...he whole story. The small scale,preliminary study...n,Reproduction, is based on recollected intake of ...oods. "This study is confounded by many,issues, th...t deal of,caution," warned Dr. Tammy Hedlund, a re...
(Date:7/24/2008)...y thermometer designed to take body temperature, f...-- Kidz-Med, Inc.,(subsidia...ts: ASFX),United States distributor of the Thermo...d to announce the results of a clinical study,cond...rsity of Milan, in,Milan, Italy, which proves that...
(Date:7/24/2008)...OLIS, France, July 24 /- Ni... top-line results from the 52-week,open label safe...letion of,the 301 phase 3 study for naproxcinod. T...and efficacy was maintained for the one-year durat...bal assessment scale. In,addition, the results sho...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Mylan Restores Availability of Generic Levothyroxine in Florida 11381 1Mylan Restores Availability of Generic Levothyroxine in Florida 11381 2Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 1Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 2Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 3Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 4Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 5Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 6Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 7Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 8Chindex International Inc Announces Results for the Quarter and Nine Months Ended December 31 2007 11378 9Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 1Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 2Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 3Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 4Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 5Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 6Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 7Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 8Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 9Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 10Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 11Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 12Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 13Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 14Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 15Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 16Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 17Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 18Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 19Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 20Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 21Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 22Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 23Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 24Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 25Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 26Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 27Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 28Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10 8 25 and 9 2 25 Respectively 3B 2007 Earnings Per Share Beat Outlook 11375 29Roche Purchases Shares in Tender Offer for Ventana 11373 1Roche Purchases Shares in Tender Offer for Ventana 11373 2Roche Purchases Shares in Tender Offer for Ventana 11373 3Roche Purchases Shares in Tender Offer for Ventana 11373 4
... Breakthrough Will Aid in Developing Therapies to ... EMERYVILLE, Calif., May 10, 2007 /PRNewswire/ -- ...development company, announced,today the first met...issues in animals through the pathway known as rev...known mechanism by which excess,cholesterol can be...
...taly--(BUSINESS WIRE)--May 14, 2007 - Acceleron Ph... therapeutics for the,treatment of musculoskeletal...ounced results of a preclinical study with,ACE-031...increase,muscle mass and strength in normal mice a... inhibits negative regulators of muscle,to increas...
Other Medicine Technology:KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens
ZyDoc offers a full medical transcription and documentation solution.
For the qualitative detection of single and multiple drugs and drug metabolites in human urine
Medicine Products: